Britain's benchmark index extended declines on Thursday as top healthcare stocks continued to decline on fears of higher U.S.
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.